Tislelizumab
CMUH-BGB-A317-CS01
Phase 2 small_molecule active
Quick answer
Tislelizumab for Esophageal Squamous Cell Carcinoma (ESCC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active